functional dyspepsia
Conditions
Interventions
Control group:mosapride citrate tablets
Experimental group:Wang Baochi Pill
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-65 years old male and female, outpatient; (2) There were symptoms of postprandial distension and early satiety, which met the diagnostic criteria of Roman IV functional gastrointestinal diseases. At least one score (degree + frequency) was greater than 4; (3) Gastroscopy was performed within 3 months before admission, and chronic non-atrophic gastritis was diagnosed; (4) C 13 or C 14 breath test was performed to detect the negative Helicobacter pylori within 3 months before enrollment; (5) agree to participate in this clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Epigastric pain syndrome (EPS) is the main symptom, and there is at least one score (degree + frequency) > 4 for mid-upper abdominal pain or burning sensation of mid-upper abdomen; (2) Patients with organic digestive tract diseases such as reflux esophagitis, peptic ulcer, digestive tract tumors, etc.; (3) suffering from thyroid disease, systemic sclerosis, systemic lupus erythematosus, chronic cholecystitis, cholecystolithiasis and other serious hepatobiliary and pancreatic diseases; or considering the possibility of intestinal obstruction; (4) Patients with severe mental disorders (HAD scale score (> 8); (5) Drugs affecting gastrointestinal motility or gastric acid secretion, neutralizing gastric acid and anti-Helicobacter pylori drugs were used within 1 week before enrollment; (6) When ALT and AST are 1.5 times higher than the normal value, the total bilirubin is 1.5 times higher than the upper limit of the normal value, and creatinine is higher than the upper limit of the normal value; (7) Patients with diabetes, epilepsy and cognitive language disorders; (8) Acupuncture and moxibustion, Qigong and other non-drug treatment; (9) Suspicion or clear history of drug and alcohol abuse; (10) allergic to Wang's Baochi Pill and its components; (11) Pregnant women, lactating women or planned pregnancies; (12) Abnormal electrocardiogram with clinical significance such as arrhythmia or abnormal Q wave, prolonged QT interval, etc.; (13) Those who have participated in other clinical trials in the past three months; (14) Researchers do not think it is suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of main symptoms; | — |
Countries
China
Contacts
Public ContactZhao shen LI
Shanghai Changhai Hospital
Outcome results
None listed